Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

First-line Zolbetuximab Plus CAPOX Prolongs Survival in CLDN18.2+/HER2– Unresectable Locally Advanced or Metastatic Gastric/GEJ Adenocarcinoma

March 22nd 2023

The addition of zolbetuximab to CAPOX led to a statistically significant improvement in progression-free survival and overall survival compared with placebo plus CAPOX for patients with Claudin-18.2–positive/HER2-negative, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

The Evolving Treatment Landscape of Biliary Tract Cancers

March 22nd 2023

Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.

Novel Targeted Therapies Under Investigation in Biliary Tract Cancers

March 22nd 2023

Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.

Understanding Endoscopy in the Realm of GI Cancers: Examining the Role of Endoscopy

March 22nd 2023

In this third episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, highlight the advantages and scope of endoscopic procedures in gastrointestinal cancer.

Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond

March 20th 2023

Oncologists review a patient profile, evaluating treatment approaches for patients with advanced HCC that have progressed beyond 1L treatment.

Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab

March 20th 2023

Experts discuss treatment options for patients unsuitable for atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.

Understanding Endoscopy in the Realm of GI Cancers: Interventional Oncology

March 17th 2023

In this second episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, explain the evolution of minimally invasive surgery and the emergence of interventional radiology in gastrointestinal cancer.

Dr. Fountzilas on Molecular Characterization in mCRC

March 16th 2023

Christos Fountzilas, MD, FACP, discusses findings from a study of molecular characterization in patients with colorectal cancer treated with cetuximab, an EGFR inhibitor, and pembrolizumab, a PD-1 inhibitor.

Investigators Struggle to Understand Causes Behind Growth of Appendix Cancer

March 16th 2023

Investigators are unclear about the factors driving the explosive growth in incidence of appendiceal cancer over the past 2 decades.

Biliary Tract Cancers: Combination Strategies With Immune Checkpoint Inhibitors

March 15th 2023

An overview on novel treatment strategies in biliary tract cancers combining immune checkpoint inhibitors with various targeted agents.

TOPAZ-1: Chemotherapy + Durvalumab in Biliary Tract Cancers

March 15th 2023

Centering discussion on the TOPAZ-1 trial of chemotherapy in combination with durvalumab, panelists consider how this regimen has impacted clinical practice.

Understanding Endoscopy in the Realm of GI Cancers: Multidisciplinary Care

March 15th 2023

In this first episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, discuss the importance of endoscopic oncology as it relates to rising cancer incidence and multidisciplinary care in gastrointestinal cancer.

NCCN Adds Ripretinib to Guidelines for Second-line Treatment of GIST

March 15th 2023

Ripretinib has been added to the National Comprehensive Cancer Network Guidelines as a preferred regimen in the second-line treatment of patients with gastrointestinal stromal tumor who are intolerant to sunitinib.

Dr. Harding on the Management of Immune-related AEs in Advanced Biliary Tract Cancer

March 14th 2023

James Harding, MD, discusses the management of immune-related adverse effects in patients with advanced biliary tract cancer.

Dr. Hwang on First-line Treatment Options in HCC

March 13th 2023

Jimmy Hwang, MD, discusses currently available first-line treatment options in hepatocellular carcinoma, and areas of continued unmet need in this space.

FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors

March 13th 2023

The FDA has placed a clinical hold on a phase 1 trial investigating the antibody-drug conjugate XMT-2056 for the treatment of patients with advanced/recurrent solid tumors that express HER2.

AB011 Plus CAPOX Demonstrates Preliminary Safety, Efficacy in Advanced Gastric/GEJ Cancer

March 13th 2023

The combination of AB011 and capecitabine/oxaliplatin was found to have a manageable safety profile and to showcase early clinical benefit when used as first-line treatment in patients with gastric cancer or gastroesophageal junction adenocarcinoma.

Real-World Evidence for Lenvatinib in Advanced HCC

March 13th 2023

Panelists share real-world evidence involving the use of lenvatinib in advanced HCC.

Patient Profile 2: Advanced HCC Treated with Lenvatinib

March 13th 2023

A panel of oncologists review a patient profile, evaluating a patient with advanced HCC treated with lenvatinib.

Dr. Wainberg on the Rationale for the Phase 3 NAPOLI 3 Trial in Patients With PDAC

March 9th 2023

Zev A. Wainberg, MD, discusses the rationale behind the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.